RareKids-CAN Offer Subsidized Services for Investigator-initiated Academic Clinical Trials

RareKids-CAN offers a range of subsidized services for investigator-initiated (academic-led) pediatric rare disease clinical trials. The goal of these services is to stretch project funds further, ensuring greater impact and cost savings. Below is the list of subsidized services offered:

 

100% Subsidized Services (RareKids-CAN will cover 100% of the cost of the following services):

    • Consultations: We will conduct a robust consultation to identify areas of needs for your project with valuable involvement from relevant sub platforms based on your project needs to ensure your project receives adequate support.
    • High-level project management: An experienced project manager will ensure efficient coordination, oversight, and successful execution from inception to completion for your clinical trial.
    • Database build (not including management): We will provide project-specific electronic case report form (e-CRF) development and database management in a validated REDCap database housed at the Women and Children’s Health Research Institute (WCHRI).
    • Data Safety Monitoring Board: From our repository of individuals with specific expertise relevant to your project, we facilitate a centralized data safety monitoring board to ensure participant safety and provide expertise on clinical trial conduct for continuation, modification, or termination.

 

50% Subsidized Services (RareKids-CAN will cover 50% of the total cost of the following services):

    • Regulatory submissions: We assist study teams in the preparation and submission of clinical trial applications, investigational testing authorizations, and single-patient study applications for regulated clinical trials to Health Canada. We will also assist in adverse event reporting.
    • Monitoring: We have a dedicated and experienced monitoring team to perform risk-based remote and on-site monitoring to meet the Health Canada required sponsor obligations.

All other services are 100% cost recovered (i.e., RareKids-CAN will not subsidize)

 

If you have a clinical trial that require these services or would like to further discuss, you can complete the project intake form.

RareKids-CAN logo

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.